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a  b  s  t  r  a  c  t
A  generally  accepted  and  validated  laboratory  model  for  smoking-associated  pulmonary  tumorigene-
sis  would  be  useful  for  both  basic  and  applied  research  applications,  such  as the  development  of  early
diagnostic  endpoints  or  the  evaluation  of modiﬁed  risk  tobacco  products,  respectively.  The  A/J  mouse
is  susceptible  for  developing  both  spontaneous  and  induced  lung  adenomas  and  adenocarcinomas,  and
increased  lung  tumor  multiplicities  were  also  observed  in  previous  cigarette  smoke  inhalation  studies.
The  present  study  was  designed  to collect  data  useful  towards  the  validation  of an  18-month  mainstream
smoke  (MS)  inhalation  model.  Male  and  female  A/J mice  were  exposed  whole-body  at  three  MS concen-
tration  levels  for  6 h/day,  and  the  results  were  compared  to  a previous  study  in  the  same  laboratory  and
with  a  similar  design.  A linear  MS  concentration-dependent  increase  in lung  tumorigenesis  was  observed
with  similar  slopes  for both  sexes  and  both  studies  and  a maximal  5-fold  increase  in  multiplicity  beyond
sham  control.  The  minimal  detectable  difference  in lung  tumor  multiplicity  for  the  current  study  was
37%.  In  the  larynx,  papillomas  were  detectable  in all  MS-exposed  groups  in a non-concentration  depend-
ent  manner.  No  other  extra-pulmonary  MS-dependent  neoplastic  lesions  were  found.  Gene  expression
signatures  of  lung  tumor  tissues  allowed  a clear  differentiation  of sham-  and  high dose  MS-exposed  mice.
In  combination  with  data from  previous  smoke  inhalation  studies  with  A/J  mice,  the  current  data  suggest
that  this  model  for MS  inhalation-induced  pulmonary  tumorigenesis  is  reliable  and  relevant,  two  crucial
requirements  towards  validation  of  such  a model.. Introduction
Cigarette smoking is a cause of severe diseases, including lung
ancer (International Agency for Research on Cancer, 2004). While
ore and more information is becoming available on the patho-
enesis of smoking-related lung cancer (US Department of Health
nd Human Services, 2010), a comprehensive understanding of the
ctual causative agents in smoke and the mechanisms involved
Abbreviations: ANOVA, analysis of variance; ETSS, environmental tobacco smoke
urrogate;  MDD, minimal detectable difference; MS,  mainstream smoke; MS-75,
S-150, MS-300, groups exposed to MS concentrations of 75, 150 and 300 mg/m3
PM, respectively; R2, coefﬁcient of determination; RLE, relative log expression; SD,
tandard deviation; SE, standard error of the mean; TPM, total particulate matter.
∗ Corresponding author at: Philip Morris International R&D, Philip Morris Prod-
cts  S.A., Quai Jeanrenaud 5, 2000 Neuchâtel, Switzerland. Tel.: +41 (58) 242 2233;
ax: +41 (58) 242 2811.
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is still missing. To some extent, this knowledge gap is related to
the lack of a generally accepted laboratory animal model for main-
stream smoke (MS) inhalation-inducible lung cancer. Such a model,
once established, could be used for etiological and mechanistic
research, for research on diagnostic and therapeutic means, and
for the evaluation of modiﬁed risk tobacco products. Such models
have recently been called for by the US FDA (US Food and Drug
Administration Center for Tobacco Products, 2012) and the US IOM
(Institute of Medicine, 2012), in particular for comparative assess-
ments.
The purpose of bioassays on carcinogenesis is to identify car-
cinogenic properties of test materials in laboratory rodents in order
to evaluate a carcinogenic potential for humans (Organisation for
Economic Co-operation and Development, 1981, 2009). In line
Open access under CC BY-NC-ND license.with regulatory guidance for conducting bioassays on carcinogene-
sis, laboratory rats and mice are most commonly exposed for an
appreciable portion of their lifespan. In the case of smoking, a car-
cinogenic potential has already been established in humans, and
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ioassays are required to model the human disease pathogenesis to
he extent possible for the above-mentioned applications. In terms
f lung cancer, laboratory rodents mainly develop peripheral pul-
onary adenomas that may  progress to adenocarcinomas, while
umans may  develop various histological types of highly inva-
ive bronchial and bronchiolar-alveolar carcinomas (Schleef et al.,
006) with an increasing fraction of adenocarcinomas over the last
ecades (Devesa et al., 2005).
Despite many years of research, no model for MS-induced
ung tumorigenesis could be established that is generally accepted
Coggins, 2010). However, there are three rather recent develop-
ents, which may  eventually qualify. (1) Lifetime MS  inhalation
tudies have been recently reported on F344 rats and B6C3F1
ice, in which statistically signiﬁcant increases in lung tumors
ere found in females (Hutt et al., 2005; Mauderly et al., 2004).
owever, the response for male rats was negative, and male
ice were not tested. Furthermore, it seems that these stud-
es have not been repeated anywhere to test for reproducibility.
2) A relatively pronounced increase in lung tumorigenicity in
ale and female Swiss mice was obtained when MS  inhalation
xposure was started immediately after birth (Balansky et al.,
007). These results seem to be reproducible in the same labo-
atory (Balansky et al., 2009), but apparently this study design
as not been reproduced in other laboratories. Furthermore, the
iological relevance of this particular exposure scenario for the
ssessment of smoking-related tumorigenesis remains to be estab-
ished. (3) A series of positive lung tumorigenesis inhalation studies
ave been conducted using whole-body exposure of A/J mice to
n environmental tobacco smoke surrogate (ETSS) (Stinn et al.,
005; Witschi, 2005). In these studies, mice were exposed for
 months followed by a 4-month post-inhalation period (5 + 4-
onth schedule), which was needed for the smoke-induced tumors
o develop beyond incidences found in sham-exposed controls.
sing the same exposure schedule, studies on MS inhalation
ere also negative at the end of the 5-month inhalation period
ut positive at the end of the 4-month post-inhalation period
Curtin et al., 2004; Stinn et al., 2010).
In an 18-month study with A/J mice, the need for a post-
nhalation period was conﬁrmed for 5- and 10-month MS
nhalation periods, but MS  inhalation for 18 months was  sufﬁcient
o elicit a concentration-dependent lung tumor response without
he need for a further post-inhalation period (Stinn et al., 2012). The
usceptibility of the A/J mouse to the development of spontaneous
nd chemically induced lung adenomas and adenocarcinomas
eems to be related to a propensity of the Kras proto-oncogene for
utation and increased transcription (Chen et al., 1994; To et al.,
006). Mutated Kras genes have frequently been found in human
ung adenocarcinomas of smokers (Porta et al., 2009). In view of the
bove, this model warrants further investigation of its reliability
nd biological relevance, two crucial requirements of toxicological
ethod validation (e.g., Interagency Coordinating Committee on
he Validation of Alternative Methods, 1997).
With the aim of generating data towards validating the A/J
ouse model, the objectives of the present study were
to generate data on intra-laboratory reproducibility of the
lung tumor response in A/J mice exposed to MS  inhala-
tion for 18 months and to discuss inter-laboratory repro-
ducibility based on published shorter-term smoke inhalation
studies;
to extend the information on model characteristics, such as
sex dependence, and concentration–response relationship, and
extra-pulmonary tissue effects;
to assess data variability and discriminatory power; andy 305 (2013) 49– 64
• to add further mechanistic data for the evaluation of the biologi-
cal relevance of the model, i.e., the gene expression signature in
tumor tissues.
2. Materials and methods
2.1. General study design
Due to the objective of reproducing the data from the previous 18-month inhala-
tion study (designated as Study 1, Stinn et al., 2012), the basic study design and
methods were very similar for the current study (Study 2). In order to align as much
as  possible to regulatory guidance available for the carcinogenicity testing of chemi-
cals (Organisation for Economic Co-operation and Development, 1981, 2009), Study
2 additionally included female mice as the second sex and the histopathological
examination of extra-pulmonary organs and tissues. For a better characterization
of  the MS concentration–response curve, a third concentration was added, which
was below the ones previously used, because the high concentration in Study 1 was
considered the maximum tolerated MS  concentration. Thus, in Study 2, male and
female mice were whole-body exposed to 75, 150, and 300 mg/m3 total particulate
matter (TPM) (MS-75, MS-150, and MS-300) for 6 h/day and 5 days/week for 18
months (interim dissection after 10 months). A sham-exposed control group was
treated the same way  except for MS  inhalation. A post-inhalation period of 2 days
was added for a satellite group of mice exposed for 18 months that were allocated
to the investigation of gene expression patterns in lung tumor tissue. This short
post-inhalation period was expected to down-regulate most of the acute MS expo-
sure related induction of gene expression in order to allow a characterization of
longer-term effects that may be characteristic for the tumorigenic process.
In  Study 1, MS was generated using the standard reference cigarette 2R4F. Due
to the diminishing stock of 2R4F cigarettes, 3R4F cigarettes were used in Study
2  for MS  generation (University of Kentucky, Lexington, KY) (for speciﬁcations
see http://www.ca.uky.edu/refcig/). Both reference cigarette types display equiv-
alent MS  composition as well as in vitro and in vivo toxicity (Roemer et al., 2012).
MS  generation was performed in basic accordance with international standards
(International Organization for Standardization, 1991, 2000). Analytical characteri-
zation of the MS was  performed as previously reported (Stinn et al., 2012).
The approval for the performance for both studies was obtained according to the
Belgium Law on Animal Protection (Belgian Federal Public Service, 2004). The studies
were performed in an AAALAC-accredited facility (Association for the Assessment
and Accreditation of Laboratory Animal Care International, 1991), where care and
use  of the mice were in accordance with the American Association for Laboratory
Animal Science (AALAS) Policy on the Humane Care and Use of Laboratory Animals
(http://www.aalas.org).
2.2.  Test system
Male and female A/J mice bred under speciﬁed pathogen-free conditions (The
Jackson Laboratory, Bar Harbor, Maine, USA) were obtained through Charles River
France (L’Arbresle, France). The age of the mice was between 6 and 10 weeks at
arrival and between 8 and 12 weeks at start of the inhalation, as in Study 1.
The  health status of six male and six female mice was  conﬁrmed serologically
(Bioreliance, Rockville, MA), bacteriologically, parasitologically (Harlan, UK), and
histopathologically. Eight of 12 mice were positive for Klebsiella oxytoca, which was
not considered to impact the study quality since there was  no pattern of character-
istic lesions that might have been associated with Klebsiella infections.
Within 1 week after arrival, the mice were individually identiﬁed with sub-
cutaneous transponders (Triple A Trading, Tiel, the Netherlands). After random
allocation to groups, the mean body weight per group at the start of exposure
was  approximately 22 g for the male and 18 g for the female mice, with relative
standard deviations (SD) of less than 11%. Twenty and 64 mice per group and sex
were allocated for the 10-month interim and 18-month ﬁnal dissection time points,
respectively. The mice were fed irradiated Harlan Teklad 2014 diet at libitum (Har-
lan,  Blackthorn, UK), except during exposure. Filtered tap water was offered during
and between exposures. Irradiated softwood granulate bedding material, type Lig-
nocel BK8/15 (Tecnilab, Someren, the Netherlands) was used. The position of the
cages in the whole-body exposure chambers was  rotated on a weekly basis. There
were at least six air changes per hour in the exposure chambers, and the equivalent
ﬂow rate through each exposure chamber was at least 80 l/min. The mean tem-
perature and the mean relative humidity in the sham-exposure chambers during
exposure was 22.3 ± 0.6 ◦C (mean ± SD) and 55.7 ± 2.6% (mean ± SD) respectively.
These conditions were considered representative of the MS  chambers as well. The
exposure period started with adaptation periods of 2, 3, 4, and 5 h/day (3 days each)
prior to the ﬁnal 6 h/day. Mice that died during the ﬁrst 6 weeks of the study were
replaced.2.3. Biological endpoints
In-life observations and determinations, necropsy, organ weights, hemato-
logy (without differentiation of leukocytes) and respiratory tract histopathology
were performed as previously described (Stinn et al., 2010). All mice that died
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pontaneously or were killed in a moribund state were necropsized and investi-
ated histopathologically in order to clarify the cause of death or the moribund
tatus. From mice scheduled for dissection after 10 months of exposure, only the
ungs were examined.
.3.1. Histopathology
All respiratory tract organs were ﬁxed in a mixture of ethanol, glycerol, acetic
cid, formaldehyde, and saline (EGAFS, ratio 40:5:5:10:40, v/v) for 1 day and there-
fter kept in 70% ethanol. The lungs were ﬁxed by intratracheal instillation with
GAFS at a constant hydrostatic pressure of 15 cm water column within 1 min. The
yes were preserved in Davidson ﬁxative, the testes in Bouin ﬁxative, the sternum in
chaffer’s solution and all other non-respiratory organs were preserved in a neutral
queous phosphate-buffered 4% solution of formaldehyde.
The histopathological examination by light microscopy was performed at four
evels of the nose (adapted from Young, 1981), three levels of the larynx (base of
he  epiglottis, arytenoid projections, vocal folds (adapted from Lewis, 1981)), and
t  two levels of the trachea including the bifurcation. Serial sectioning of the lungs
as  performed at 300 m steps from all mice scheduled for dissection after 10
nd 18 months of inhalation as well as from all mice that died spontaneously or
ere killed in a moribund state. From all non-respiratory tract organs one or two
epresentative slides were examined per organ. All parafﬁn slides were routinely
tained with hematoxylin/eosin. In addition, respiratory tract slides were stained
ith Alcian Blue/periodic acid-Schiff to demonstrate goblet cells. Neoplastic lesions
f  non-respiratory tract tissues were additionally stained with phosphor tungsten
cid hematoxylin (PTAH) and according to Masson–Goldner (except for systemic
umors from the low and medium dose group animals at terminal sacriﬁce).
In  addition to the respiratory tract tissues, the following organs were ﬁxed,
rocessed, and histopathologically examined to clarify whether long-term MS
nhalation induced any extra-pulmonary carcinogenesis by in this model: both
drenal glands, aorta abdominalis, bone (os femoris with joint), bone marrow (cervi-
al,  thoracic, sternum, lumbar, os femoris), brain (cerebrum, cerebellum, brain stem,
ippocampus, paraventricular parts), caecum, diaphragm, ductus thoracicus, both
pididymes, eye with optic nerve, gall bladder, gross lesions observed, Harderian
lands, heart (left and right ventricle, septum), small intestine (duodenum, jejunum,
leum), large intestine (colon, rectum), both kidneys and ureters, both lacrimal
lands (infraorbitalis, extraorbitalis), liver, lymph nodes (axillary, bronchial, cervi-
al,  inguinal, mandibular, mediastinal, mesenteric, paraaortic, poplietus), mammary
land, mucosa (mouth), muscle (skeletal), nerve (sciatic), esophagus, olfactory
ulb, both ovaries and the mesovarium, pancreas, pituitary, both preputial glands,
rostate, salivary glands (submandibular, parotid), both seminal vesicles, skin,
pleen, sternum, stomach and forestomach, both testes, thymus, both thyroids
including parathyroids), tissue masses or tumors, tongue (inclusive base), urethra,
rinary bladder, uterus (including cervix and both uterine horns and oviducts), and
agina.
Histopathological preparations of respiratory tract organs were performed at
hilip Morris Research Laboratories GmbH, Cologne, Germany. The histopathologi-
al evaluation was performed by Histovia GmbH, Overath, Germany. All pulmonary
roliferative lesions were classiﬁed according to international classiﬁcations and
riteria (Brambilla et al., 2001; Dungworth et al., 2001). Histopathological prepa-
ations of non-respiratory tract organs were performed by the Laboratory of
harmacology and Toxicology GmbH & Co KG, Hamburg, Germany. The histopatho-
ogical examination was  performed by Toxicologic Pathology Consultancy (Kiel,
ermany). Classiﬁcation of neoplastic lesions in the various organs except the lungs
as  performed (according to the criteria deﬁned by Mohr, 2001). All histopatholog-
cal examinations were performed without knowledge of the treatment groups.
.3.2. RNA isolation from lung tumors and gene expression analysis
Gene expression analysis was performed on lung tumor samples from the MS-
00  and sham control groups. Frozen sections (20 m)  from whole lung tissue were
laced on sterilized glass slides and stained with cresyl violet. Total tissues from
ingle lung tumors were collected from these slides using laser capture micro-
issection (Zeiss, Oberkochen, Germany) except of one slide, which was preserved
or  the histopathological characterization of the tumor. The tumor tissues were
mmediately lysed with Qiazol lysis buffer (Qiagen, Hilden, Germany). RNA was
solated using the miRNeasy mini-Kit (Qiagen) according to the supplier’s manual.
ll RNA samples had an RNA integrity number of at least six.
Transcriptome analysis was performed following the manufacturer’s recom-
endation in the Affymetrix Gene Chip® Expression Analysis Technical Manual
Santa Clara, CA) as previously speciﬁed (Gebel et al., 2010). The quality of Affymetrix
EL ﬁles was checked by utilizing the R packages affy, gcrma, and affyPLM (Bolstad
t  al., 2005; Gautier et al., 2004; Wu et al., 2005). Normalized Unscaled standard
rror (NUSE) box plots and relative log expression (RLE) box plots were generated
o identify the potential outliers. A CEL ﬁle was identiﬁed as an outlier if the median
f  its NUSE was  beyond 1.05 or the median of its RLE was  beyond 0.1. Potential spa-
ial  artifacts on arrays were checked by plotting the image and pseudo image for all
he  arrays. Microarray expression values were generated from the CEL ﬁles using
ackground correction, quantile normalization, and median polish summarization.
 probe set was  ﬁltered out when the 95% quantile of the log 2 expression value was
ess  than 7. To extract a speciﬁc and robust gene signature which can discriminate
he tumors of differently exposed mice, supervised machine-learning approachesy 305 (2013) 49– 64 51
including SAM (Tusher et al., 2001) and support vector machine (Cortes and Vapnik,
1995)  were applied in a 10-fold cross-validation procedure. A preliminary pathway
analysis was  performed using DAVID (Huang et al., 2008, 2009).
2.4. Statistical evaluation
For continuous data, in general the arithmetic mean and the standard error (SE)
are given as descriptive statistics, but for chemical-analytical data describing the
test atmosphere the SD was calculated. Continuous data, such as organ weights,
were statistically evaluated using a 1-way analysis of variance (ANOVA) followed
by  a Tukey test (Zar, 1984).
Statistical evaluation of all neoplastic ﬁndings was carried out using an exact
Trend Test (Peto et al., 1980). All calculations were performed using the Pathdata-
System statistical program (Rotkreuz, Switzerland). Non-neoplastic ﬁndings were
statistically analyzed with a non-survival adjusted Trend Test (Armitage, 1955). For
all  neoplastic (except lung tumors) and non-neoplastic ﬁndings a one-sided Fisher’s
exact test (pairwise comparisons of control groups vs. concentration groups) was
performed. For the lung tumor incidence, the Fisher Exact Test was applied for over-
all  analysis followed by pairwise comparison. For the lung tumor multiplicity, the
1-way ANOVA was applied followed by pairwise comparison using the Tukey test
(Zar,  1984).
For the calculation of the discriminatory power (  ˇ = 0.2) of various study designs,
the minimal detectable difference (MDD) was calculated by comparing the slopes of
two linear regression lines. A t-distributed test statistic was calculated (Sachs, 1978)
by using the same variance components of actual study data for both regression
lines. When male and female groups were available, the arithmetic mean of the
two datasets was  taken. The slope of the ﬁrst regression line was ﬁtted to the study
data. The second slope was  varied in such a way  that the test statistics just reached
statistical signiﬁcance (p < 0.05). The difference between both slopes, expressed as
percent, was taken as MDD.
For an estimate of the lung tumor size, the number of consecutive cross sections
showing the same individual lung tumor or precancerous lesion was multiplied with
the  300 m distance of consecutive step serial sections. The proportion between
adenomas and carcinomas within the different exposure groups was calculated by
the  quotient of carcinomas and the sum of adenomas and carcinomas on an indi-
vidual animal basis. Animals were included in this type of evaluation, if at least one
lung adenoma or carcinoma was present. These data were compared statistically by
ANOVA followed by pairwise comparison using the Tukey test (Zar, 1984).
All tests were considered statistically signiﬁcant at p ≤ 0.05. No correction for
multiple testing was  performed.
3. Results
3.1. Inhalation exposure
All test atmospheres were reproducibly generated throughout
the 18-month inhalation period at the MS  target concentrations
of 75, 150, and 300 mg  TPM/m3 (Table 1). This resulted in propor-
tional concentrations of other aerosol constituents such as carbon
monoxide, nicotine, acetaldehyde and acrolein. An exception for
this linear dilution was seen for formaldehyde. The concentrations
in the current study (Study 2) corresponded well to those previ-
ously observed in the Study 1 (Stinn et al., 2012).
Inhalation exposure to MS  was  monitored by determining
carboxyhemoglobin proportions, which were 0.3 ± 0.1, 10.7 ± 0.5,
19.3 ± 0.7, and 36.5 ± 1.1% for males and 0.3 ± 0.1, 10.3 ± 0.3,
19.8 ± 0.5, and 37.0 ± 1.3% for females in the sham, MS-75, MS-150,
and MS-300 groups, respectively (mean ± SE; N = 8 per group at two
time points during the study). The carboxyhemoglobin proportions
correlated with the carbon monoxide concentrations in the test
atmospheres and were similar to those reported in Study 1.
3.2. In-life observations and determinations
In the groups scheduled for 18 months of inhalation, mortality
rates of 58, 48, 34, and 45% for males and of 39, 39, 28, and 20%
for females were observed in sham, MS-75, MS-150, and MS-300
groups, respectively. The trend to higher mortality in the sham-
exposed compared to MS-exposed mice was also observed in Study
1. However, the overall mortality in Study 2 was higher than in
Study 1. This may  have been at least partly due to a dilated car-
diomyopathy which occurred mainly during the ﬁrst months of the
study and was more pronounced in male than in female mice. In
52 W. Stinn et al. / Toxicology 305 (2013) 49– 64
Table 1
Analytical characterization of test atmospheres.
Parameter (mg/m3) N Male groups Female groups
Sham MS-75 MS-150 MS-300 Sham MS-75 MS-150 MS-300
Total particulate matter 400 <1.6a 74 ± 5 148 ± 10 294 ± 15 <1.6a 75 ± 5 152 ± 10 295 ± 17
Carbon  monoxide 401 <5a 129 ± 7 238 ± 15 449 ± 26 <5a 128 ± 8 239 ± 15 449 ± 25
Nicotine 28 <0.03a 2.3 ± 0.6 4.5 ± 0.8 11.0 ± 1.8 <0.03a 2.7 ± 0.7 5.4 ± 0.8 12.0 ± 1.9
Formaldehyde 20 – 0.14 ± 0.03 0.20 ± 0.03 0.33 ± 0.06 – 0.11 ± 0.02 0.18 ± 0.03 0.27 ± 0.03
Acetaldehyde 20 – 6.6 ± 0.4 12.2 ± 0.7 24.9 ± 2.0 – 6.4 ± 0.8 12.3 ± 1.2 23.3 ± 1.6
Acrolein 20 – 0.60 ± 0.08 1.16 ± 0.11 2.31 ± 0.26 – 0.59 ± 0.11 1.18 ± 0.13 2.15 ± 0.23
N S-300
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wote: All data are given as means and standard deviation. MS-75, MS-150 and M
espectively.
a Below quantiﬁcation limit.
ffected mice, the hearts were enlarged and displayed a grey-white
iscoloration. Microscopically, an inﬁltration of neutrophilic gra-
ulocytes and lymphocytes was observed as well as a calciﬁcation
nd necrosis of heart muscle cells. The lack of a functional dysferlin
ene apparently predisposes the A/J mouse to this cardiomyopa-
hy, which can be aggravated by stress (Chase et al., 2009; Han
t al., 2007; Wenzel et al., 2007). This extent and incidence of car-
iomyopathy was not recorded in Study 1, although calciﬁcation of
he heart was also observed in some mice.
The body weight of male sham-exposed mice increased during
he ﬁrst 12 months of the inhalation period and tended to be con-
tant until the end of the 18-month inhalation period (Fig. 1). A clear
S concentration–response effect was observed in the ﬁrst months
f the inhalation period. The body weight of the MS-150 and MS-
00 groups was approximately 90% of that the sham-exposed group
ig. 1. Body weight development, male and female mice (group means; SE values
ere between 0.2 and 0.6 g).: MS at target concentration of 75, 150 and 300 mg total particulate matter/m3,
at the end of the inhalation period, similar to that observed in
Study 1. For female mice, the body weight development of the
sham-exposed group and the MS-75 group were very similar with
maximal body weight differences of 5%. The body weights of female
MS-150 and MS-300 groups decreased during the ﬁrst 5 weeks of
the inhalation period to approximately 88% of that of the sham-
exposed group and later increased to a level of approximately 95%
of that of the sham-exposed group, with maximal differences of 3%
amongst them between exposure months 7 and 14.
3.3. Organ weights and gross pathology
Lungs were weighed with trachea and larynx attached. With
increasing MS  concentration, weights increased similarly in both
Studies 1 and 2, and the effect was statistically signiﬁcant for the
MS-300 groups in comparison to sham control (Fig. 2). There was
no sex difference. Absolute heart weights did not change with
MS inhalation in Study 2, however, heart weights relative to body
weight were found to be statistically signiﬁcantly increased in the
male MS-300 and the female MS-150 and -300 groups (data not
shown).
On the larynx, statistically signiﬁcantly higher incidences of dis-
colored foci were observed in the MS-300 groups of both sexes. On
the lungs, the incidence of various macroscopic observations, such
as diffuse discoloration, discolored foci, grey-white nodules within
the parenchyma, and discoloration of bronchial lymph nodes, was
statistically signiﬁcantly increased in the MS-150 and/or MS-300
groups of both sexes. Also, hernia of the diaphragm was statistically
signiﬁcantly increased in the female MS-300 group.
Of the hematological parameters investigated, erythrocyte
count, hematocrit, hemoglobin content and parameters derived
thereof were increased by up to 32% in both sexes in an MS
concentration-dependent manner (data not shown). No effects
were observed for white blood cells and platelets.
3.4. Non-neoplastic changes in the upper respiratory tract
The nasal cavity and the larynx have been the target organs
for neoplastic changes in previous long-term MS  inhalation studies
with rats (Mauderly et al., 2004), mice (Hutt et al., 2005), and ham-
sters (Bernfeld et al., 1979; Dontenwill et al., 1973). The respective
epithelia were, therefore, carefully histopathologically examined
at various section levels.
Hyperplastic and metaplastic epithelial changes, at times with
corniﬁcation, were observed in an MS  concentration-dependent
manner at the various section levels of the nose and larynx after
18 months of MS  inhalation (Table 2). In addition, degenerative
changes were observed, such as olfactory epithelium atrophy,
loss of nerve bundles in the lamina propria, and congestive
changes at submucosal glands that were associated with ductal
respiratory epithelium metaplasia in the ducts of the Bowman’s
glands. Inﬂammatory inﬁltrates in the epithelial submucosa were
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Table  2
Non-neoplastic ﬁndings in nose and larynx following 18 months of MS inhalation.
Tissue/ﬁnding Parametera Males Females
Sham MS-75 MS-150 MS-300 Sham MS-75 MS-150 MS-300
Nose, level 1
Respiratory epithelium
Hyperplasia Severity 0.0 ± 0.0 0.5 ± 0.1 2.4 ± 0.1 3.6 ± 0.1 0.0 ± 0.0 1.1 ± 0.1 2.9 ± 0.1 3.8 ± 0.1
Squamous metaplasia Severity 0.0 ± 0.0 0.0 ± 0.0 0.6 ± 0.1 3.0 ± 0.2 0.0 ± 0.0 0.0 ± 0.0 0.9 ± 0.2 3.1 ± 0.1
Corniﬁcation Severity 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.4 ± 0.1 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.4 ± 0.1
Mixed inﬂammatory cells Incidence 0 3 0 34 3 0 0 23
Degeneration Incidence 0 0 0 3 0 0 9 15
Respiratory region, lamina propria
Mixed inﬂammatory cells Incidence 0 3 0 23 5 0 0 27
Respiratory region, lumen
Homog. eosinoph. material Incidence 8 15 27 63 3 14 59 69
Necrotic inﬂammatory cells Incidence 0 0 0 51 3 0 0 46
Submucosal gland
Ectasia/congestion Incidence 39 21 51 29 10 30 30 46
Nose,  level 2
Respiratory epithelium
Hyperplasia Severity 0.0 ± 0.0 0.1 ± 0.1 0.8 ± 0.1 2.9 ± 0.1 0.0 ± 0.0 0.2 ± 0.1 1.4 ± 0.1 3.2 ± 0.1
Squamous metaplasia Severity 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 1.4 ± 0.2 0.0 ± 0.0 0.0 ± 0.0 0.1 ± 0.1 1.4 ± 0.2
Mixed inﬂammatory cells Incidence 0 3 0 26 0 0 0 13
Respiratory region, lamina propria
Mixed inﬂammatory cells Incidence 0 0 0 26 3 0 0 13
Respiratory region, lumen
Homog. eosinoph. material Incidence 4 0 5 54 0 0 22 50
Necrotic inﬂammatory cells Incidence 0 0 0 17 3 0 0 29
Olfactory epithelium
Atrophy Severity 0.0 ± 0.0 0.3 ± 0.1 0.4 ± 0.1 0.6 ± 0.2 0.1 ± 0.1 0.7 ± 0.1 0.8 ± 0.1 0.2 ± 0.1
Respiratory metaplasia Severity 0.0 ± 0.0 0.7 ± 0.2 3.3 ± 0.2 4.2 ± 0.2 0.1 ± 0.0 0.8 ± 0.1 3.1 ± 0.3 4.7 ± 0.1
Loss  of nerve bundles Severity 0.0 ± 0.0 0.6 ± 0.2 3.4 ± 0.3 4.9 ± 0.1 0.0 ± 0.0 0.9 ± 0.2 3.6 ± 0.2 4.8 ± 0.1
Olfactory region, lumen
Homog. eosinoph. material Incidence 0 0 8 35 0 0 18 28
Necrotic inﬂammatory cells Incidence 0 0 0 12 3 0 0 17
Bowman’s glands
Ectasia/congestion Incidence 0 15 92 100 5 17 87 100
Respiratory metaplasia Incidence 0 15 89 100 5 17 87 100
Nose,  level 3
Olfactory epithelium
Atrophy Severity 0.0 ± 0.0 0.0 ± 0.0 0.3 ± 0.1 1.4 ± 0.1 0.1 ± 0.1 0.2 ± 0.1 0.8 ± 0.1 0.8 ± 0.1
Respiratory metaplasia Severity 0.0 ± 0.0 0.0 ± 0.0 1.8 ± 0.2 2.6 ± 0.1 0.1 ± 0.0 0.0 ± 0.0 2.0 ± 0.1 2.7 ± 0.1
Loss  of nerve bundles Severity 0.0 ± 0.0 0.0 ± 0.0 1.9 ± 0.2 3.4 ± 0.1 0.1 ± 0.0 0.2 ± 0.1 2.3 ± 0.2 3.0 ± 0.1
Eosinophilic deposits Severity 0.0 ± 0.0 0.0 ± 0.0 0.9 ± 0.2 1.8 ± 0.2 0.1 ± 0.1 0.0 ± 0.0 1.3 ± 0.2 1.9 ± 0.2
Olfactory region, lumen
Homog. eosinoph. material Incidence 0 3 16 77 10 8 40 56
Necrotic inﬂammatory cells Incidence 0 0 0 29 0 0 2 31
Bowman’s glands
Ectasia/congestion Incidence 4 0 87 97 8 3 91 100
Respiratory metaplasia Incidence 4 0 84 97 8 3 91 100
Sinus  maxillaries
Necrotic inﬂammatory cells Incidence 0 0 0 14 0 0 0 13
Nose,  level 4
Olfactory epithelium
Atrophy Severity 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.3 ± 0.1 0.0 ± 0.0 0.1 ± 0.1 0.2 ± 0.1 0.2 ± 0.1
Respiratory metaplasia Severity 0.0 ± 0.0 0.0 ± 0.0 0.7 ± 0.1 1.3 ± 0.2 0.1 ± 0.0 0.0 ± 0.0 0.5 ± 0.1 1.3 ± 0.1
Loss  of nerve bundles Severity 0.0 ± 0.0 0.0 ± 0.0 0.5 ± 0.1 1.1 ± 0.2 0.0 ± 0.0 0.0 ± 0.0 0.5 ± 0.1 1.2 ± 0.2
Eosinophilic deposits Severity 0.0 ± 0.0 0.0 ± 0.0 0.1 ± 0.1 0.7 ± 0.2 0.0 ± 0.0 0.0 ± 0.0 0.2 ± 0.1 1.3 ± 0.2
Olfactory region, lumen
Homog. eosinoph. material Incidence 0 0 3 29 3 0 13 27
Bowman’s glands
Ectasia/congestion Incidence 0 0 43 66 5 3 33 75
Respiratory metaplasia Incidence 4 0 43 66 5 3 33 75
Larynx, base of epiglottis
Cuboidal epithelium
Hyperplasia Severity 0.4 ± 0.1 2.8 ± 0.1 3.5 ± 0.3a –b 0.6 ± 0.1 3.0 ± 0.2 3.7 ± 0.1 –b
Squamous metaplasia Severity 0.4 ± 0.1 2.9 ± 0.2 4.3 ± 0.2 5.0 ± 0.0 0.3 ± 0.1 2.8 ± 0.2 4.0 ± 0.1 5.0 ± 0.0
Corniﬁcation Severity 0.0 ± 0.0 0.9 ± 0.3 3.5 ± 0.4 4.9 ± 0.1 0.0 ± 0.0 0.5 ± 0.2 2.9 ± 0.2 5.0 ± 0.0
Mixed inﬂammatory cells Incidence 0 3 7 38 0 0 3 18
Metaplastic epithelium
Hyperplasia Severity 0.0 ± 0.0 0.6 ± 0.2 3.2 ± 0.4 3.6 ± 0.2 0.0 ± 0.0 0.8 ± 0.3 2.8 ± 0.3 3.6 ± 0.1
Papillary hyperplasia Incidence 0 21 45 24 0 38 50 18
Submucosal gland epithelium
Degeneration/atrophy Incidence 0 77 97 88 0 85 100 92
Metaplasia/hyperplasia Incidence 0 13 39 69 0 6 5 68
Submucosal gland duct epith.
Metaplasia/hyperplasia Incidence 0 90 96 91 0 94 95 97
54 W. Stinn et al. / Toxicology 305 (2013) 49– 64
Table 2 (Continued)
Tissue/ﬁnding Parametera Males Females
Sham MS-75 MS-150 MS-300 Sham MS-75 MS-150 MS-300
Submucosal gland
Dilatation/congestion Incidence 0 70 100 97 0 88 100 90
Interstitial ﬁbrosis Incidence 0 3 14 39 0 3 5 53
Larynx, arytenoid projections, ventral depression
Cuboidal epithelium
Squamous metaplasia Severity 0.0 ± 0.0 0.2 ± 0.1 2.8 ± 0.4 4.9 ± 0.0 0.0 ± 0.0 0.2 ± 0.1 3.2 ± 0.3 5.0 ± 0.0
Corniﬁcation Severity 0.0 ± 0.0 0.0 ± 0.0 2.3 ± 0.5 4.9 ± 0.1 0.0 ± 0.0 0.0 ± 0.0 2.5 ± 0.4 5.0 ± 0.0
Larynx, arytenoid projections, ﬂoor
Pseudostratiﬁed epithelium
Squamous metaplasia Severity 0.0 ± 0.0 1.8 ± 0.2 4.8 ± 0.1 5.0 ± 0.0 0.1 ± 0.1 1.5 ± 0.2 4.4 ± 0.1 5.0 ± 0.0
Corniﬁcation Severity 0.0 ± 0.0 0.3 ± 0.2 4.3 ± 0.2 5.0 ± 0.0 0.0 ± 0.0 0.2 ± 0.1 4.0 ± 0.2 5.0 ± 0.0
Papillary hyperplasia Incidence 0% 61 50 22 0 49 36 7
Larynx, vocal cords, lower medial region
Squamous epithelium
Hyperplasia Severity 0.3 ± 0.1 0.8 ± 0.2 3.7 ± 0.1 4.2 ± 0.1 0.0 ± 0.0 0.5 ± 0.1 3.8 ± 0.1 4.0 ± 0.0
Corniﬁcation Severity 0.1 ± 0.1 0.2 ± 0.1 4.2 ± 0.3 5.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 3.8 ± 0.3 5.0 ± 0.0
Papillary hyperplasia Incidence 0 0 18 3 0 0 21 2
Larynx, vocal cords, upper medial region
Pseudostratiﬁed epithelium
Squamous metaplasia Severity 0.0 ± 0.0 0.8 ± 0.1 4.3 ± 0.3 5.0 ± 0.0 0.0 ± 0.0 0.6 ± 0.1 3.8 ± 0.3 5.0 ± 0.0
Corniﬁcation Severity 0.0 ± 0.0 0.0 ± 0.0 3.9 ± 0.4 5.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 3.0 ± 0.4 5.0 ± 0.0
Larynx, vocal folds
Pseudostratiﬁed epithelium
Hyperplasia Severity 0.0 ± 0.0 0.0 ± 0.0 1.8 ± 0.2 2.8 ± 0.1 0.0 ± 0.0 0.0 ± 0.0 1.9 ± 0.2 3.2 ± 0.1
Squamous metaplasia Severity 0.0 ± 0.0 0.1 ± 0.1 1.9 ± 0.3 3.6 ± 0.2 0.1 ± 0.1 0.0 ± 0.0 2.0 ± 0.3 4.0 ± 0.1
Corniﬁcation Severity 0.0 ± 0.0 0.0 ± 0.0 0.3 ± 0.2 2.2 ± 0.3 0.0 ± 0.0 0.0 ± 0.0 0.4 ± 0.2 3.1 ± 0.3
Submucosal gland
Dilatation/congestion Incidence 0 0 3 18 0 3 7 7
Squamous epithelium
Hyperplasia Severity 0.0 ± 0.0 0.1 ± 0.1 3.0 ± 0.2 4.3 ± 0.1 0.0 ± 0.0 0.2 ± 0.1 3.1 ± 0.2 4.0 ± 0.1
Corniﬁcation Severity 0.0 ± 0.0 0.0 ± 0.0 2.9 ± 0.4 4.9 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 2.9 ± 0.4 5.0 ± 0.0
Papillary hyperplasia Incidence 0 0 19 3 0 0 10 0
Note: N = 26–48 mice per group. Statistically signiﬁcant ﬁndings compared to the sham-exposed group are printed in bold. MS-75, MS-150 and MS-300: MS  at target
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ccasionally observed in the apical nose and at the base of the
piglottis. Eosinophilic amorphous material and aspired plant
aterial, which probably stems from the bedding material, were
bserved in the lumen of the larynges of several mice. The inci-
ences of these ﬁndings were statistically signiﬁcantly higher in the
ig. 2. Weight of lungs with larynx and trachea, male mice of the previous Study 1 (Stinn
tatistical tests: 1) signiﬁcantly different from sham.l scoring.
MS-300 groups (up to 50%) compared to the sham control groups.
Slight hyperplastic and metaplastic epithelial changes were also
observed at the carina of the tracheal bifurcation and in transverse
sections (data not shown). There was no sex difference for these
non-neoplastic effects in the upper respiratory tract.
 et al., 2012) and male and female mice of the current Study 2 (group means ± SE).
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.5. Neoplastic lesions in the upper respiratory tract
After 18 months of MS  inhalation, papillomas were found at
he base of epiglottis and the ﬂoor of the larynx (level of ary-
enoids projections). The incidences for this benign neoplastic
nding were 0, 10, 74, and 13% in male mice and 0, 16, 65,
nd 3% for female mice for sham, MS-75, MS-150, and MS-300
roups, respectively. At the same epithelial sites and with a similar
iphasic concentration–response relationship, papillary hyperpla-
ia was observed (Table 2), which was considered to be a precursor
esion for the epithelial papillomas. There was no evident sex differ-
nce. Likewise, in mice that died spontaneously or were sacriﬁced
ue to their moribund state, the incidence of laryngeal papillomas
as highest in the MS-150 group. The lower incidence and severity
f ﬁndings in the MS-300 group cannot readily be explained, but
ight be related to the most pronounced sensitivity to irritation at
his site of the respiratory tract (Haussmann et al., 1998).
Individual neoplastic lesions were found in other parts of the
espiratory tract, which were not considered to be related to MS
nhalation. Plasmocytoma were found in two male mice of the sham
ontrol group. Esophageal squamous cell carcinomas were found in
 female mouse of the MS-150 group that died spontaneously and
n a male mouse of the MS-150 group that was sacriﬁced due to its
oribund status.
.6. Proliferative pulmonary lesions
Three types of pulmonary proliferative lesions, i.e., a nodular
yperplasia of the alveolar epithelium, bronchioloalveolar adeno-
as, and bronchioloalveolar carcinomas were observed both in
ham- and MS-exposed mice. The nodular hyperplasia appeared
s poorly circumscribed (nodular) areas of increased cellularity
ue to the proliferation of cuboidal cells lining the alveoli. These
ells morphologically resembled normal type II pneumocytes with
ittle atypia and single mitotic ﬁgures. Within the lesion, the
ronchioloalveolar architecture was still detectable without any
ompression of the surrounding lung tissue. The benign bronchi-
loalveolar adenomas appeared as a solid focal area of increased
ellularity obliterating the underlying alveolar architecture. Ade-
omas did not imitate the alveolar structure and formed glandular,
apillary, or solid structures. They were embedded as single islands
n hyperplastic areas or appeared as solid nodules sharply demar-
ated and compressing the adjacent lung tissue. A mild cellular
typia and single mitotic ﬁgures were observed. Malignant bron-
hioloalveolar carcinomas appeared as well demarcated areas
f increased cellularity with a papillary or solitary morphology
mbedded in adenomatous tissue. In contrast to adenomas, a higher
egree of pleomorphism and anaplasia of the cells was indicative
or malignancy. Malignant cells appeared as single foci embedded
n poorly differentiated areas or formed conﬂuent lesions. The pro-
ression from adenomas to carcinomas appeared to be transient
nd discrimination was  sometimes difﬁcult.
After 10 months of MS  inhalation, no clear tumorigenic effect
as observed (Table 3). A statistically signiﬁcant 3-fold increase
n adenoma multiplicity was observed in the male MS-150 group,
ut this may  be a chance ﬁnding as there was no concentra-
ion/response relationship and no parallel ﬁnding in the female
ouse groups. This lack of a tumorigenic effect at 10 months of
S  inhalation is in general agreement with the previous ﬁndings
n Study 1 (Stinn et al., 2012).
After 18 months of MS  inhalation, a clear tumorigenic effect
as observed (Table 3). Similar to Study 1, the level of hyperpla-
ia remained relatively low regardless of air or MS  exposure which
n view of the increased tumor levels would suggest that this is
 transient preneoplastic ﬁnding during mouse lung tumorigen-
sis. The incidence and multiplicity of pulmonary adenomas andy 305 (2013) 49– 64 55
carcinomas increased in an MS  concentration-dependent manner.
For some of the proliferation parameters, statistically signiﬁcant
differences were obtained between individual MS  concentration
levels. The most robust and differentiating parameter seemed to be
the combined multiplicity of adenomas and carcinomas, because
all MS  concentrations could be statistically signiﬁcantly differ-
entiated except between MS-75 and sham control groups. The
increases in tumor multiplicity relative to sham were very simi-
lar to those observed for male mice in the previous Study 1 (Stinn
et al., 2012) (Fig. 3). In general, the MS-induced tumorigenic effect
was more pronounced for adenomas than for carcinomas (Table 3,
Fig. 3). This resulted in a lower proportion of carcinomas rel-
ative to both tumors types in MS-  compared to sham-exposed
mice (41, 36, 24, and 23% for males and 37, 33, 14, and 29% for
females in sham, MS-75, MS-150, and MS-300 groups, respec-
tively), which in contrast to the previous Study 1 (Stinn et al.,
2012) was not statistically signiﬁcant in the current study. Fold
increases in female mice were higher than in male mice, which
might be related to the lower background of spontaneous tumors
in female compared to male mice of this study. A most pronounced
6-fold increase was obtained for adenomas in the female MS-300
group, whereas the increase for carcinomas was only up to 4-fold
(Fig. 3). The proliferative lesions were distributed across the ﬁve
lung lobes in general accordance with the respective tissue mass
(data not shown).
The size of the proliferative lesions increased with the tumori-
genic progression from the nodular hyperplasia to adenoma to
carcinoma (Fig. 4). There was  a numerical trend towards lower
tumor sizes with increasing MS  concentration, similar to the obser-
vations in the previous Study 1 (Stinn et al., 2012).
Metastatic tumors were found in the lungs of three mice: an
undifferentiated mesenchymal tumor with pronounced hemor-
rhage was  found in the lungs of a sham-exposed male mouse; the
respective primary neoplasm was not found. A squamous cell car-
cinoma was  identiﬁed as a metastasis in the lung of a female mouse
of the MS-75 group; the respective primary neoplasm was located
within the stomach with additional metastases in diaphragm and
spleen. In a male mouse of the MS-300 group, three adenomas
were found in the left lung and approximately 50 presumably bron-
chogenic metastases in the right anterior lobe. These mice were not
included in the determination of the primary lung tumor multiplic-
ity.
3.7. Non-neoplastic changes in non-respiratory tract organs and
tissues
Type, incidence, and severity of all other non-neoplastic ﬁnd-
ings observed in smoke-exposed animals did not differ signiﬁcantly
from those seen in the sham control animals and were similar for
animals dissected after 18 months of inhalation as well as for ani-
mals that died during the course of the study or were killed in a
moribund status. These alterations were considered to be within
the normal range of background pathology commonly observed
in mice of this strain and age. The only MS inhalation-dependent
effect observed was an increase in incidence and severity of
histiocytosis and yellow-brown pigment accumulation in the
bronchial lymph nodes of mice of the MS-150 and MS-300 groups
(data not shown).
3.8. Neoplastic lesions in non-respiratory tract organs and tissues
The major non-respiratory neoplastic ﬁndings were rhab-
domyosarcomas. This neoplasm invaded the skeletal muscle
surrounding either the axial or proximal appendicular skeleton and
was characterized by pleomorphic cells with abundant eosinophilic
cytoplasm, multiple nuclei, and cross striations. In mice dissected
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Table 3
Proliferative pulmonary lesions after 18 months of MS  inhalation.
Inhalation periods
(months)
Lesion Parameter Males Females
Sham MS-75 MS-150 MS-300 Sham MS-75 MS-150 MS-300
10 N 20 20 20 20 20 20 19 20
All  proliferative
lesions
Multiplicity M 0.70 0.70 1.60 1.00 1.05 0.50 1.63 1.65
SE 0.18 0.16 0.33 0.23 0.25 0.15 0.28 0.33
Test 1) 2)
Factor 1.00 1.00 2.29 1.43 1.00 0.48 1.55 1.57
Incidence (%) 50 55 75 65 65 40 84 80
Test
Factor 1.00 1.10 1.50 1.30 1.00 0.62 1.29 1.23
Nodular
hyperplasia
Multiplicity M 0.10 0.25 0.40 0.40 0.30 0.15 0.58 0.55
SE 0.07 0.10 0.13 0.13 0.11 0.08 0.19 0.14
Test
Factor 1.00 2.50 4.00 4.00 1.00 0.50 1.93 1.83
Incidence (%) 10 25 35 35 30 15 42 50
Test
Factor 1.00 2.50 3.50 3.50 1.00 0.50 1.40 1.67
Bronchioloalveolar
adenoma
Multiplicity M 0.40 0.40 1.20 0.55 0.60 0.30 0.74 1.10
SE 0.13 0.11 0.26 0.17 0.20 0.13 0.19 0.30
Test 1) 2)
Factor 1.00 1.00 3.00 1.38 1.00 0.50 1.23 1.83
Incidence (%) 35 40 65 40 40 25 53 50
Test
Factor 1.00 1.14 1.86 1.14 1.00 0.63 1.33 1.25
Bronchioloalveolar
carcinoma
Multiplicity M 0.20 0.05 0 0.05 0.15 0.05 0.32 0
SE 0.09 0.05 0 0.05 0.08 0.05 0.22 0
Test
Factor 1.00 0.25 0 0.25 1.00 0.33 2.11 0
Incidence (%) 20 5 0 5 15 5 16 0
Test
Factor 1.00 0.25 0 0.25 1.00 0.33 1.07 0
Bronchioloalveolar
adenoma and
carcinoma
Multiplicity M 0.60 0.45 1.20 0.60 0.75 0.35 1.05 1.10
SE 0.17 0.11 0.26 0.17 0.19 0.13 0.31 0.30
Test 2)
Factor 1.00 0.75 2.00 1.00 1.00 0.47 1.40 1.47
Incidence (%) 45 45 65 45 55 30 53 50
Test
Factor 1.00 1.00 1.44 1.00 1.00 0.55 1.05 1.10
18 N 25 33 37 34 39 36 45 48
All  proliferative
lesions
Multiplicity M 1.60 2.12 3.43 4.62 1.13 2.17 3.13 4.83
SE 0.22 0.25 0.27 0.28 0.14 0.24 0.22 0.40
Test 1) 2) 1) 3) 4) 1) 1) 3) 4)
Factor 1.00 1.33 2.15 2.89 1.00 1.92 2.77 4.27
Incidence (%) 80 85 97 100 72 94 98 98
Test 1) 1) 3) 1) 1) 1)
Factor 1.00 1.06 1.21 1.25 1.00 1.31 1.36 1.36
Nodular
hyperplasia
Multiplicity M 0.28 0.45 0.35 0.41 0.31 0.33 0.29 0.56
SE 0.09 0.14 0.10 0.11 0.08 0.09 0.09 0.11
Test
Factor 1.00 1.62 1.25 1.47 1.00 1.06 0.94 1.81
Incidence (%) 28 27 27 32 28 31 22 44
Test
Factor 1.00 0.96 0.96 1.14 1.00 1.11 0.79 1.57
Bronchioloalveolar
adenoma
Multiplicity M 0.80 1.00 2.35 3.21 0.49 1.25 2.38 3.06
SE 0.18 0.15 0.25 0.29 0.11 0.18 0.20 0.30
Test 1) 2) 1) 3) 4) 1) 2) 1) 3)
Factor 1.00 1.25 2.94 4.01 1.00 2.55 4.88 6.24
Incidence (%) 52 67 92 97 38 72 93 92
Test 1) 2) 1) 3) 1) 1) 2) 1) 3)
Factor 1.00 1.29 1.77 1.87 1.00 1.89 2.45 2.42
Bronchioloalveolar
carcinoma
Multiplicity M 0.52 0.67 0.73 1.00 0.33 0.58 0.47 1.21
SE 0.14 0.15 0.15 0.20 0.11 0.12 0.11 0.17
Test 1) 3) 4)
Factor 1.00 1.29 1.40 1.92 1.00 1.76 1.42 3.67
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Table  3 (Continued)
Inhalation periods
(months)
Lesion Parameter Males Females
Sham MS-75 MS-150 MS-300 Sham MS-75 MS-150 MS-300
Incidence (%) 40 42 49 59 23 47 33 65
Test 1) 1) 4)
Factor 1.00 1.05 1.23 1.48 0.58 1.18 0.83 1.63
Bronchioloalveolar
adenoma and
carcinoma
Multiplicity M 1.32 1.67 3.08 4.21 0.82 1.83 2.84 4.27
SE 0.20 0.21 0.26 0.28 0.14 0.23 0.23 0.36
Test 1) 2) 1) 3) 4) 1),2) 1) 3) 4)
Factor 1.00 1.27 2.33 3.19 1.00 2.23 3.46 5.21
Incidence (%) 72 82 97 100 54 92 96 96
Test 1) 2) 1) 3) 1) 1) 1)
Factor 1.00 1.14 1.35 1.39 1.00 1.65 1.78 1.78
Note: N: number of mice per group for scheduled dissection. MS-75, MS-150 and MS-300: MS at target concentration of 75, 150 and 300 mg total particulate matter/m3,
respectively. All data represent results pooled from all lung lobes. Factor is the fold increase in multiplicities and incidences in MS  exposure groups relative to those in the
sham  group.
Statistical tests: 1) signiﬁcantly different from sham.
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c)  MS-150 signiﬁcantly different from MS-75.
) MS-300 signiﬁcantly different from MS-75.
) MS-300 signiﬁcantly different from MS-150.
fter 18 months of MS  inhalation, rhabdomyosarcomas were found
n moderate incidence in all groups including the sham control
roup. In mice that died spontaneously during the course of the
tudy or were killed in a moribund state, the incidence of this fatal
umor was much higher. This resulted in overall incidences of 43,
6, 30, and 36% in male mice and 27, 33, 23, and 19% in female mice
n the sham, MS-75, MS-150, and MS-300 groups. Statistical eval-
ations did not reveal any signiﬁcant difference in the incidence
etween sham control and MS-exposed groups. Rhabdomyosarco-
as  seem to be relatively frequent in A/J mice (34% reported by
andau et al., 1998).
The incidence of all neoplastic lesions in non-respiratory tract
rgans diagnosed in this study did not indicate a signiﬁcant differ-
nce between MS-exposed and sham control groups, when tested
or a positive trend with respect to dose rates (according to Peto
t al., 1980) (data not shown). There was no indication that any of
hese neoplasms were associated to the bronchioloalveolar adeno-
as  and carcinomas observed in this study.
ig. 3. Relative increases in lung tumor multiplicities (adenomas and carcinomas) of gro
ontrol  group in the previous Study 1 (Stinn et al., 2012) and male and female mice of the3.9. Reproducibility
For the most robust parameter of the lung tumor response, i.e.,
the combined multiplicity of adenomas and carcinomas, there was
a remarkable intra-laboratory reproducibility for the 18-month
MS inhalation study design between Study 1 (male mice; Stinn
et al., 2012) and the current Study 2 (male and female mice)
(Fig. 5). The combined tumor multiplicities of male and female
mice from both studies were very similar and correlated highly
with the MS  concentration if linear regression analysis was  applied
(R2 = 0.92). When considering the adenoma multiplicities sepa-
rately, the reproducibility and the MS  concentration–response
relationship was  still acceptable (R2 = 0.90). Carcinoma multiplic-
ities in the current were only about half as high as those of
the previous study, for reasons unknown, resulting in a rela-
tively poor regression among the three study parts (R2 = 0.36).
This may  be related to the above-described MS effect on the
carcinoma/adenoma ratio. The reproducibility of increases in
ups exposed to mainstream smoke for 18 months in comparison to sham-exposed
 current Study 2 (group means).
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cig. 4. Size of pulmonary proliferative lesions of the previous Study 1 (Stinn et al.
onths of mainstream smoke inhalation. Sizes were estimated based on the numbe
ection  thickness. Statistical tests: 1) signiﬁcantly different from sham; 2) MS-150 s
ultiplicity relative to the sham-exposed control group (Fig. 3) of
oth tumors combined was relatively high for male mice of both
2tudies 1 (Stinn et al., 2012) and 2 (R = 0.94), while that for the
hree study parts including females was lower (R2 = 0.70), which
as due to the steeper MS  concentration–response relationship
ig. 5. Reproducibility of the concentration–response relationship for the combined
ultiplicity of adenomas and adenocarcinomas (group means ± SE) after 18 months
f  mainstream smoke inhalation with no post-inhalation (18 + 0-month schedule:
tudy 1 (Stinn et al., 2012) and current Study 2). Filled and open symbols repre-
ent male and female mice, respectively. Linear regressions (dashed line) and 95%
onﬁdence intervals (dotted lines) were calculated.) and of male and female mice of the current Study 2 (group means ± SE) after 18
rial histological sections cut in sequence for the same lesion and multiplied by the
cantly different from MS-75; 3) MS-300 signiﬁcantly different from MS-75.
found in female mice of Study 2 compared to that found in male
mice of both studies.
3.10. Discriminatory power
An optimal comparative study design would use several con-
centrations of MS  of the cigarette types and compare the slopes
of the concentration–response relationships. A minimal detectable
difference (MDD) based on slopes was  calculated assuming a sig-
niﬁcance level of  ˛ = 0.05 and an intended statistical power of 20%
(  ˇ = 0.2). For the two 18-month studies, Study 1 (Stinn et al., 2012)
and Study 2 (current study), MDDs of 51 and 37%, respectively, were
determined for the combined multiplicities of adenomas and car-
cinomas (Table 4). For the 5 + 4-month schedule, MDDs of 17 and
10% were determined (Stinn et al., 2010, 2012). These differences
are related to the number of MS  concentration levels, the degree
of linearity of the concentration–response relationship, and/or the
group sizes available at the respective ﬁnal dissections, while the
relative standard error tended to be higher in the 5 + 4-month stud-
ies than in the 18-month studies. The most pronounced increase in
tumor multiplicity in Study 1 was  obtained with a combination of
10 months of MS  inhalation and 8 months of post-inhalation (Stinn
et al., 2012). With the three concentration levels used, an MDD of
25% was  obtained. Thus, depending on the group sizes and the num-
ber of concentration levels employed, MDDs between 10 and 50%
can be achieved.
3.11. Molecular tumor differentiation
In lung tumor tissues harvested by laser capture micro-
dissection, a gene signature composed of 408 genes was identiﬁed,
which discriminated between tumors stemming from mice
exposed to MS-300 for 18 months + 2 days post-inhalation and their
respective sham-exposed control mice. A clear pattern of up- and
down-regulation of gene expression was  observed by hierarchical
clustering distinguishing the two exposure types (Fig. 6). A mean
prediction accuracy of 95% across all samples was obtained. All
tumors from the MS-exposed mice were correctly predicted. In the
sham-exposure group, one tumor sample was predicted wrongly,
and the gene signature of another sample was not discriminative.
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Table  4
Discriminatory power for the combined multiplicities of adenomas and adenocarcinomas.
Inhalation schedule Sexa MS  concentration
levelsb
Group size at scheduled
dissection (range)
Minimal detectable
difference (%)
Reference
18 + 0 M 3 22–36 51 Study 1 (Stinn et al., 2012)
M  or F 4 25–48 37c Study 2 (current study)
10  + 8 M 3 25–36 25 Study 1 (Stinn et al., 2012)
5  + 4 M 3 95–96 17 Stinn et al. (2010)
24–39 10 Study 1 (Stinn et al., 2012)
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b Including sham control.
c Averaged between sexes.
umor tissue of both groups included both adenomas and carcino-
as; no differentiation between these tumor types was possible on
he basis of the gene expression signature.
A preliminary pathway analysis revealed that genes related
o ﬁve biological processes were upregulated in tumors derived
rom MS-exposed mice: chromatin and chromosome organization,
egulation of actin, RNA splicing, small GTPase-mediated signal
ransduction, and Ras protein signal transduction. While a more
etailed analysis of the gene expression in both tumor and non-
umor tissues is warranted, these data indicate that in general the
umors arising spontaneously in sham-exposed mice are qualita-
ively different from those arising in MS-exposed mice.
. Discussion
Long-term inhalation studies with cigarette smoke are tech-
ically demanding, and many design variations are possible and
ave been applied. So far, no generally accepted study design has
volved. Most studies have been performed with laboratory rats
nd mice. In many cases, these studies have not demonstrated an
ncrease in lung tumorigenesis (Coggins, 2010). Thus, there is still
ig. 6. Gene signature heatmap discriminating the tumor tissues from mainstream
moke (MS-300)- and sham-exposed mice. Tissues were harvested by micro-
issection after 18 months of inhalation and 2 days of post-inhalation to avoid
cute smoke exposure-related gene expression changes. The gene expression value
n  the heatmap is row centered and the positive and negative gene expression val-
es  are colored with red and green, respectively. Up and down regulated genes are
learly clustered into different groups by hierarchical clustering. Tumor types: Ad,
denoma; Ca, carcinoma; ND, not determined (unclassiﬁed neoplastic nodule).(For
nterpretation of the references to color in this ﬁgure legend, the reader is referred
o  the web version of the article.)a need for such models for the improvement of mechanistic and
etiologic knowledge, as models for developing chemopreventive,
diagnostic, or therapeutic interventions, and for efﬁcacy testing of
potentially reduced or modiﬁed risk tobacco products.
The strain A mouse was among the ﬁrst mouse strains used for
the purpose of investigating MS  tumorigenesis (Essenberg, 1952;
Lorenz et al., 1943). More recently, reproducible positive effects for
lung tumorigenesis have been obtained in inhalation studies with
ETSS according to a 5 + 4-month schedule of inhalation and post-
inhalation in order to allow smoking-related tumor expression
(reviewed in Witschi, 2005). Consequently, this model using the
5 + 4-month schedule was  also applied to a series of MS  inhalation
studies (Curtin et al., 2004; Gordon and Bosland, 2009; Stinn et al.,
2010). More recently, a complex MS  inhalation study comparing
inhalation and post-inhalation periods of various durations (Study
1) determined that long-term inhalation, i.e., for 18 months, was
sufﬁcient to demonstrate an MS  concentration-dependent increase
in lung tumors without the need of a post-inhalation period (18 + 0
schedule) (Stinn et al., 2012).
The concentration–response relationship for 18 months of MS
inhalation observed in Study 1 was reproduced and reﬁned in
the current Study 2. Thus, intra-laboratory reproducibility was
achieved. The use of two different generations of a ﬁltered refer-
ence cigarette (2R4F and 3R4F) for MS  generation had no inﬂuence
on the tumor response, as would be expected based on the results of
comparative chemical-analytical, in vitro, and in vivo studies show-
ing no apparent differences between the two reference cigarettes
(Roemer et al., 2012).
Long-term MS  inhalation studies with the A/J mouse using a
similar study design have not been reported by other laboratories.
Thus, information on inter-laboratory reproducibility of using MS
inhalation on this mouse strain could only be obtained by analyzing
tumor response data obtained with the more common 5 + 4-month
schedule. Of the published studies, some had very low group sizes
(D’Agostini et al., 2001), and some used nose-only exposure (Hamm
et al., 2007) instead of whole-body exposure as in the current
study; these studies were not included in the current assessment
of reproducibility. A direct comparison of both whole-body and
nose-only exposure modes in a 5 + 4-month schedule did not ﬁnd
a statistically signiﬁcant MS  effect after nose-only exposure while
whole-body exposure was  positive (Curtin et al., 2004). For an inter-
laboratory comparison of the results of the 5 + 4-month schedule,
therefore, only four whole-body MS  inhalation studies qualiﬁed
(Fig. 7): the ﬁrst was the whole-body exposure part of the above
comparative study (Curtin et al., 2004); the second included the
A/J mouse as one of several strains that were compared in terms of
cancer susceptibility (Gordon and Bosland, 2009); the third was a
study experimentally conducted at TNO Quality of Life, Zeist, the
Netherlands (Stinn et al., 2010); and the fourth was  part of the
complex study design of Study 1 (Stinn et al., 2012). The tumor mul-
tiplicities obtained in the four available studies were reproducible.
The correlation obtained by linear regression analysis of the com-
bined dataset of the four studies was lower (R2 = 0.68) than that of
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Fig. 7. Reproducibility of the concentration–response relationship for the combined
multiplicity of adenomas and adenocarcinomas (group means ± SE) after 5 months
of  mainstream smoke inhalation followed by 4 months of post-inhalation (5 + 4-
month schedule: Study 1 (Stinn et al., 2012) and previously published studies (Curtin
et  al., 2004; Gordon and Bosland, 2009; Stinn et al., 2010)). Filled and open symbols
represent male and female mice, respectively. Linear regressions (dashed line) and
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Fig. 8. Age-dependence and reproducibility of spontaneous lung tumor devel-
opment. Control tumor multiplicities from sham-exposure groups of recent
mainstream smoke inhalation studies (Curtin et al., 2004; Gordon and Bosland,
2009; Stinn et al., 2010; Study 1: Stinn et al., 2012; and the current Study 2)
with B6C3F1 mice, only female mice were used with the idea of5% conﬁdence intervals (dotted lines) were calculated.
he 18 + 0-month dataset obtained in one laboratory. In part, this
ay  be due to the lower effect size after 5 + 4 months, which was
wo to three times smaller than after 18 months. This was  appar-
ntly associated with a higher relative variability within studies
nd may  have also contributed to a larger inter-laboratory vari-
bility. In these four MS  studies using the 5 + 4-month schedule,
here might be inter-study differences regarding diet, inhalation
aboratory techniques, histopathology, and tumor classiﬁcation, all
f which may  contribute to a relatively smaller reproducibility
ompared to the intra-laboratory comparison with the 18-month
chedule.
In the above 5 + 4 schedule studies, two ﬁlter (1R4F and 2R4F)
nd one unﬁltered (1R1: Gordon and Bosland, 2009) reference
igarette type were used. Although the study with the MS from the
nﬁltered reference cigarette type had the lowest absolute tumor
ultiplicities, the slope was the same as that for studies with ﬁl-
ered reference cigarette types. Thus, this model cannot distinguish
etween ﬁltered and unﬁltered cigarettes, which may  be related
o the fact that these studies were dosed and normalized to TPM
r mass of the particulate phase, which was identiﬁed to drive
he tumorigenic activity of MS  in this model (rather than the gas
hase, Stinn et al., 2010). In human smokers, an approximately 40%
ower risk for lung cancer-related mortality for ﬁlter compared to
on-ﬁlter cigarette types was observed (Lee and Sanders, 2004;
S Department of Health and Human Services, 2004). This differ-
nce is probably not only related to differences in cancer potency
etween the cigarette types but may  also encompass differences
n smoking behavior and potential other variables that might have
ffected lung tumor risk over time. Nevertheless, it would remain
o be investigated whether either the 5 + 4- or the 18 + 0-monthwere plotted against a background of historic control data for A/J mice (Stoner and
Shimkin, 1982). Filled and open symbols represent male and female mice, respec-
tively.
schedules would be able to actually detect such differences in a
direct comparison within one study.
In a series of ETSS inhalation studies with the 5 + 4-month sched-
ule within a single laboratory (Witschi, 2005), a correlation of
R2 = 0.67 was  obtained at tumor multiplicities of approximately 2
in the high exposure groups. This is identical to the inter-laboratory
correlation for the MS  inhalation studies following the 5 + 4-month
schedule and thus another indication of the robustness of the A/J
mouse model.
Most of the above-discussed studies have been conducted with
male A/J mice. The current study showed that there is no major
difference between sexes in the MS  concentration–response rela-
tionship of the absolute tumor multiplicities, although the relative
increase in tumor multiplicity in comparison to the sham-exposed
control group was  higher for female mice than for male A/J mice.
This is probably related to an incidentally lower spontaneous tumor
background in sham-exposed female compared to male A/J mice in
the current study and in comparison to an otherwise quite robust
historic dataset (Fig. 8). In rather comprehensive previous assess-
ments of the utility of the A/J mouse for carcinogenicity testing,
no consistent sex-related differences in spontaneous as well as
chemically induced tumorigenicity were observed (Maronpot et al.,
1986; Shimkin and Stoner, 1975). Also, in ETSS inhalation studies,
no apparent sex difference was observed (Witschi, 2005). In con-
trast, MS  inhalation in rats lead to a statistically signiﬁcant increase
in lung tumorigenesis in female rats, with no observable sponta-
neous background tumor rate, while the tumor response for male
rats did not reach statistical signiﬁcance compared to a non-zero
control (Mauderly et al., 2004). In lifetime MS  inhalation studyincreasing the statistical power of the study (Hutt et al., 2005). It
remains to be determined whether female mice would indeed be
more susceptible to MS-induced lung tumorigenesis.
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The average relative MS-induced increase in tumor multiplicity
eyond control was similar at the end of the 18-month inhalation
tudy to that after the shorter-term 5 + 4-month schedule (Curtin
t al., 2004; Stinn et al., 2010, 2012). A relative increase of this size
as also found in A/J mice pretreated with 4-(methylnitrosamino)-
-(3-pyridyl)-1-butanone (NNK) and in KrasLA2 transgenic mice in
 5 + 4-month schedule, even though this increase was  obtained on
 much higher overall level of tumor multiplicity in the transgenic
ice (Takahashi et al., 2010). In the current study, the most pro-
ounced effect was observed for adenomas in female mice (6-fold
ncrease over control); for the combined adenomas and carcino-
as  in female mice, a 5-fold increase was observed. This was about
alf of the increase observed in a 30-month MS  inhalation study
ith female B6C3F1 mice (Hutt et al., 2005), which, however, only
sed one high MS  concentration and has not been reproduced to
ate. It is noteworthy, though, that MS  inhalation in these more
ecent studies was shown to be tumorigenic in both resistant and
usceptible mouse strains as well in transgenic mice. The B6C3F1
ouse is considered to be resistant to lung tumorigenesis (multi-
licity of 0.1 for spontaneous tumors at an age of approximately
2 months), while A/J mice are rather susceptible (average multi-
licity of 1–2 for males and females at approximately 20 months
f age, Fig. 8). Another life-time MS  inhalation study with female
6C3F1 mice was more or less negative, although a numerically
igher tumor incidence was reported for the MS-exposed com-
ared to the sham-exposed mice (Henry and Kouri, 1986). In the
atter study, mice were nose-only exposed to intermittent short
aily periods of high MS  concentrations, which is different to the
hole-body 6-h continuous exposure to diluted MS  concentrations
n the more recent positive study (Hutt et al., 2005). Interestingly,
n average relative increase in tumor multiplicity of approximately
.5-fold was observed after exposure to high concentrations of ETSS
Witschi, 2005), similar to that observed in MS  inhalation studies
s discussed above.
This rather robust increase in relative tumor multiplicity by
moke inhalation in the A/J mouse model is remarkable, although
ig. 9. Differential effect of overall study duration (A) and mainstream smoke inhalation p
ultiplicity of lung adenomas and adenocarcinomas (data from Study 1 (Stinn et al., 2012)y 305 (2013) 49– 64 61
much higher dynamic effects (up to 50-fold) were observed after
administering individual carcinogens (Shimkin and Stoner, 1975).
The tumor response in MS  inhalation studies seems only to be
dependent on the MS  concentration and not on the durations of
the inhalation or post-inhalation periods providing that several
months of MS  inhalation are used. Thus, it is also not depend-
ent on the accumulated MS  dose. However, the slope of the MS
concentration–response relationship for 18 months inhalation is
approximately 3-fold steeper than that of the 5 + 4-month sched-
ule (Figs. 5 and 7), which could erroneously be interpreted as an
increased response due to a higher accumulated dose. A more
detailed analysis of tumor multiplicity data obtained in the pre-
vious Study 1 (Stinn et al., 2012), though, revealed that there is
an increase in the slope of the MS  concentration–response rela-
tionship with the duration of the post-inhalation period or, rather,
with the age of the mice upon ﬁnal dissection (Fig. 9A), while
there is no increase in this slope upon prolonged MS  inhalation
periods to the same ﬁnal study duration or age (Fig. 9B). An age-
dependent impact on the slope of the concentration–response
relationship can indeed be expected in view of the supra-linear
age-dependence of the spontaneous tumor development (Fig. 8).
Considering a similar development of spontaneous and induced
tumors, steeper dose–response relationships should be expected
in long-term rather than in shorter-term chronic studies.
Comparing various exposure scenarios, the factor between
induced and control tumor multiplicities seems to be the most
robust measure of tumorigenesis in this model. Within a given
study design with speciﬁed inhalation and post-inhalation periods,
though, the concentration–response relationship should still be
the main parameter to be evaluated in studies with the objective
to compare MS  generated from different cigarette types. For this
purpose, the current dataset on MDDs provides information that
can be used to determine group sizes to ﬁt a certain study design
and to provide the required discriminatory power. The MDDs that
can be obtained for the MS  tumorigenesis model – if used accord-
ing to OECD guidelines (Organisation for Economic Co-operation
eriod (B) on the slope of the concentration–response relationship for the combined
). Numbers in the ﬁgure legend represent months of inhalation plus post-inhalation.
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nd Development, 2009) in terms of dose levels and group size,
re compatible to the discriminatory power that was  determined
or chemical, in vitro, and subchronic inhalation studies with MS
Oldham et al., 2012).
Pulmonary tumorigenesis in the A/J mouse is dependent on
he presence and transcriptional activity of a mutated Kras onco-
ene (Chen et al., 1994; To et al., 2006). Previous studies in mouse
ung tumorigenesis models showed a lack of mutational effects
n Kras by smoke inhalation, which has been interpreted as being
ndicative of a tumor promoting rather than an initiating activity
f smoke (Wang et al., 2005; Witschi et al., 2002). This would be
onsistent with the results of applications of the two-stage carci-
ogenesis model to epidemiological data (Hazelton et al., 2005).
owever, while a higher multiplicity of tumors can be seen after
S inhalation, it has not been clear whether these are more of the
ame (promotion) or qualitatively different tumors (initiation and
romotion) compared to those developing spontaneously during
ham exposure. Histopathologically, the tumors of MS-  and sham-
xposed mice are not different. Also, their distribution within the
ungs is not different. In the current and in previous A/J mouse stud-
es discussed above, lung tumors in smoke-exposed mice were on
verage smaller and there was a trend to a lower degree of malig-
ancy compared to those in sham-exposed mice. Both effects may,
owever, be due to a delayed tumorigenic process by concomi-
ant smoke exposure compared to spontaneous tumorigenesis, as
reviously discussed (Stinn et al., 2010, 2012).
In the current study, a clear difference between tumor tissues
rom MS-  and sham-exposed mice was evident based on a gene
xpression signature, which clearly discriminated MS-exposed tis-
ues from sham-exposed tissues with an overall predictive success
ate of 95%. The tissues used for the gene expression analysis were
arvested after a 2-day post-inhalation period in order to allow
ecovery of acute smoking-related gene expression effects, such as
hose regulated by the aryl hydrocarbon receptor (AhR). A rapid
ecovery of acute smoke exposure effects on gene regulation has
een observed in previous studies (Gebel et al., 2010; Haussmann
t al., 2009), and indeed the induction of cyp1a1 as the most
rominent representative of these acute AhR-dependent effects
ecreased from approximately 300-fold to approximately 2-fold
n non-tumor tissue in the 2-day post-inhalation period in the cur-
ent study (more details to be published elsewhere). Nevertheless,
he qualitative difference of the tumors of MS-  and sham-exposed
ice may  be related to a sustained change in gene expression due
o MS  inhalation lasting longer than the 2-day recovery period.
his interpretation is favored by the 95% accuracy in allocation of
umors to MS  exposure on the basis of the gene expression signa-
ure. This is more accurate than one could expect based on a roughly
-fold increase in MS-induced tumor multiplicity beyond control,
hich theoretically could be based on 1/4 of tumors having devel-
ped spontaneously and 3/4 having speciﬁcally been induced by
he smoke exposure.
Inﬂammatory effects may  be involved in the tumorigenesis of
S in this model. Such effects were investigated and discussed in
etail in Study 1 (Stinn et al., 2012), but were not assessed in the
urrent study. In order to provide an indication of the reproducibil-
ty of inﬂammatory effects, the major inﬂammatory endpoint in
his type of study, i.e., the accumulation of neutrophils in the lungs
nalyzed upon bronchoalveolar lavage, can be compared among
tudies. The percentage of neutrophils in Study 1 at the end of
he 5-month inhalation period at an MS  concentration of 298 mg
PM/m3 was 33% relative to all cells harvested. In a previous study
y the same authors but conducted in a different laboratory, 31%
eutrophils were found at 288 mg  TPM/m3 (Stinn et al., 2010). In
nother study after 22 weeks of inhalation exposure to the MS
f a non-ﬁlter reference cigarette at 250 mg  TPM/m3, 44 and 33%
eutrophils were found for male and female A/J mice, respectivelyy 305 (2013) 49– 64
(March et al., 2006). Applying nonlinear regression to the results
of the three studies conducted in three different laboratories, a
reasonable inter-laboratory reproducibility for this major inﬂam-
matory endpoint with an R2 of 0.90 was obtained.
There are some limitations inherent to this A/J mouse model
for MS-induced pulmonary tumorigenesis. The most striking dif-
ference between this murine model and the human situation is
the lack of any reduction of the lung cancer risk in the model
upon cessation of MS  inhalation, while the relative risk for devel-
oping lung cancer in former smokers decreases with the duration
since smoking cessation (US Department of Health and Human
Services, 1990). Another limitation is the apparent balance of pro-
tumorigenic activities with the delaying or inhibiting activities of
concomitant MS  exposure, which requires the inclusion of post-
inhalation periods at least after shorter-term chronic MS inhalation
periods (Stinn et al., 2012). While this is not so much a limitation
in long-term comparative inhalation studies, e.g., for a comparison
of various types of cigarettes, a situation of smoking cessation or
switching to a potential modiﬁed risk tobacco product after having
smoked conventional cigarettes cannot be modeled by this ani-
mal  model, and misleading results would be obtained upon such
application. Furthermore, there is no real relationship between the
MS inhalation duration (or accumulated dose) and an increase in
lung tumor multiplicity over the sham-exposed control using this
A/J mouse model, while smoking duration has been identiﬁed as
an important parameter determining the risk for developing lung
cancer in humans (Flanders et al., 2003; Hazelton et al., 2005),
although with the least impact on adenocarcinoma among the
major smoking-associated histologic types of cancer (Kenﬁeld et al.,
2008). Lung cancer in humans shows a high malignancy and is often
associated with metastasis leading to a fatal outcome. In the cur-
rent A/J model, MS-induced lung cancers are not the cause of death
during the study, which may  be due to the lower malignancy com-
pared to the human situation and due to the fact that no metastasis
is induced by MS  inhalation.
In conclusion, data have been accumulated suggesting that the
A/J mouse model for long-term MS  inhalation-induced pulmonary
tumorigenesis is reliable and relevant, two basic requirements
towards validation of such models. Reliability was  shown for intra-
and inter-laboratory reproducibility, the robustness using historic
data on spontaneous and ETSS-induced tumorigenesis, and the
power to discriminate MS  from different cigarette types within
limits. The model is dependent on a number of design parame-
ters, such as the exposure mode, the exposure schedule, the age
at ﬁnal dissection, and the extent of serial sectioning of the lungs.
Strict adherence to the deﬁned study protocol may allow compar-
ative studies for the evaluation of potential modiﬁed risk tobacco
products. A further corroboration of the biological relevance of the
model requires a growing mechanistic understanding of the patho-
geneses of both human and mouse pulmonary tumorigenesis.
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